Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology

MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Mark Lotz, R.Ph., vice president, regulatory affairs and  the appointment of Wayne Saville, M.D., vice president, clinical oncology. "The addition of Mr. Lotz and Dr. Saville add expertise and substantial depth to Xencor's drug development team as we move more XmAb® candidates forward into clinical development," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "Mark's...